Scholar Rock Holding Past Earnings Performance
Past criteria checks 0/6
Scholar Rock Holding's earnings have been declining at an average annual rate of -25.3%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 25.1% per year.
Key information
-25.3%
Earnings growth rate
-2.9%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -25.1% |
| Return on equity | -285.3% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Scholar Rock Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -226 | 62 | 0 |
| 30 Jun 24 | 0 | -204 | 59 | 0 |
| 31 Mar 24 | 0 | -183 | 54 | 0 |
| 31 Dec 23 | 0 | -166 | 49 | 0 |
| 30 Sep 23 | 0 | -159 | 47 | 0 |
| 30 Jun 23 | 0 | -160 | 44 | 0 |
| 31 Mar 23 | 0 | -166 | 43 | 0 |
| 31 Dec 22 | 33 | -135 | 43 | 0 |
| 30 Sep 22 | 37 | -131 | 43 | 0 |
| 30 Jun 22 | 43 | -125 | 43 | 0 |
| 31 Mar 22 | 47 | -112 | 42 | 0 |
| 31 Dec 21 | 19 | -132 | 40 | 0 |
| 30 Sep 21 | 18 | -122 | 38 | 0 |
| 30 Jun 21 | 16 | -109 | 35 | 0 |
| 31 Mar 21 | 15 | -97 | 32 | 0 |
| 31 Dec 20 | 15 | -86 | 28 | 0 |
| 30 Sep 20 | 20 | -71 | 26 | 0 |
| 30 Jun 20 | 21 | -64 | 24 | 0 |
| 31 Mar 20 | 22 | -57 | 23 | 0 |
| 31 Dec 19 | 20 | -51 | 21 | 0 |
| 30 Sep 19 | 13 | -54 | 20 | 0 |
| 30 Jun 19 | 8 | -49 | 17 | 0 |
| 31 Mar 19 | 3 | -51 | 16 | 0 |
| 31 Dec 18 | 0 | -49 | 14 | 0 |
| 30 Sep 18 | 0 | -43 | 11 | 0 |
| 30 Jun 18 | 0 | -38 | 9 | 0 |
| 31 Mar 18 | 0 | -29 | 6 | 0 |
| 31 Dec 17 | 0 | -25 | 5 | 0 |
| 31 Dec 16 | 0 | -16 | 4 | 0 |
Quality Earnings: 2QK is currently unprofitable.
Growing Profit Margin: 2QK is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2QK is unprofitable, and losses have increased over the past 5 years at a rate of 25.3% per year.
Accelerating Growth: Unable to compare 2QK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2QK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 2QK has a negative Return on Equity (-285.33%), as it is currently unprofitable.